Similar results were achieved with neoadjuvant nab-paclitaxel 260 mg/m2 every 2 weeks (q2w) followed by vinorelbine and trastuzumab for stage I–III HER2-positive breast cancer [23]. The gene discussed is ERBB2; the disease is breast cancer.